Physician profile
David W Luck
NPI 1962445726
$3,528.47
in general payments reported to CMS, 2019-2025
29 companies · $656 in 2025
The $656 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $285 · 2021: $335 · 2022: $554 · 2023: $880 · 2024: $819 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,354.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $627.65 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $277.45 | 2022-2025 | |
| Abbvie INC. | $271.02 | 2022-2025 | |
| Lilly USA, LLC | $260.42 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $260.22 | 2022-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $259.81 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.13 | 2020-2024 | Ofev, Jardiance |
| Glaxosmithkline, LLC. | $158.23 | 2020-2025 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $127.09 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $118.71 | 2020-2025 | Airsupra, Farxiga |
| Astellas Pharma US INC | $112.16 | 2023-2024 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $105.31 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $103.34 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $99.68 | 2022-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $86.79 | 2024-2025 | Wavewriter Alpha Prime 16, Bodyguardian |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $83.90 | 2022-2025 | Repatha, Repatha, Otezla |
| Xeris Pharmaceuticals, INC. | $67.58 | 2020-2024 | Gvoke Hypopen |
| Daiichi Sankyo INC. | $42.29 | 2022-2024 | Injectafer |
| Biohaven Pharmaceutical Holding Company LTD. | $40.90 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.28 | 2020-2022 | |
| Abbott Laboratories | $24.73 | 2021 | |
| Corcept Therapeutics | $20.25 | 2023 | Korlym |
| Merck Sharp & Dohme LLC | $19.19 | 2024 | Gardasil, Gardasil 9 |
| Cequr Corporation | $19.04 | 2024 | Cequr Simplicity |
| Dynavax Technologies Corporation | $17.98 | 2024 | Heplisav-B |
| Biohaven Pharmaceuticals, INC. | $14.31 | 2021 | |
| Nabriva Therapeutics, Plc | $12.79 | 2021 | |
| Alexion Pharmaceuticals, INC. | $12.54 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Luck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.